** Shares of medical device maker Delcath Systems DCTH.O up 2% at $16.43

** H.C. Wainwright raises PT on DCTH to $29 from $24

** DCTH's intention to enter into a Medicaid National Drug Rebate $(NDRA)$ Agreement "is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth" - Wainwright

** By entering into the NDRA, DCTH's Hepzato kit would be made available to all Medicaid and Medicare Advantage programs, increasing their access considerably

** Company's Hepzato Kit is a drug-device combination product for cancer treatment

** DCTH has begun the process of entering into NDRA and expects it to become effective from Q3 of 2025

** Stock has risen over 34% YTD, as of last close

(Reporting by Juby Babu in Mexico City)

((Juby.Babu@thomsonreuters.com;))